missing translation for 'onlineSavingsMsg'
Learn More
Learn More
SARS-CoV-2 Spike RBD LlaMABodyTM Bivalent VHH HuIgG2 Fusion Antibody, R&D Systems™
Llama Monoclonal Antibody
Brand: R&D Systems LMAB10870-100
This item is not returnable.
View return policy
Description
Spike RBD Monoclonal antibody specifically detects Spike RBD in SARS-CoV-2 samples. It is validated for Blocking Assay
Specifications
| Spike RBD | |
| Monoclonal | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. | |
| Llama | |
| Protein A or G purified from cell culture supernatant | |
| RUO | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 6 months, -20 to -70°C under sterile conditions after reconstitution. |
| Blocking Assay | |
| L009.2.69H | |
| Blockade of Receptor-ligand Interaction | |
| YP_009724390.1 | |
| Human embryonic kidney cell HEK293-derived SARS-CoV-2 Spike RBD as immunogen for bivalent Llama VHH-Human IgG2 Fusion Antibody., Arg319-Phe541, Accession # YP_009724390.1 | |
| 100 μg | |
| Primary | |
| SARS-CoV-2 | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction